300194 福安药业
已收盘 12-11 15:00:00
资讯
新帖
简况
福安药业(300194)披露子公司收到药品注册证书,12月10日股价上涨1.56%
证券之星 · 12-10 22:15
福安药业(300194)披露子公司收到药品注册证书,12月10日股价上涨1.56%
福安药业(300194.SZ)子公司产品纳入国家医保药品目录
智通财经 · 12-08
福安药业(300194.SZ)子公司产品纳入国家医保药品目录
福安药业:多维度提升管理效能
证券之星 · 12-02
福安药业:多维度提升管理效能
福安药业(300194.SZ):“头孢托仑匹酯颗粒”获得药品注册证书
智通财经 · 12-01
福安药业(300194.SZ):“头孢托仑匹酯颗粒”获得药品注册证书
福安药业:子公司积极拓展海外市场
证券之星 · 11-28
福安药业:子公司积极拓展海外市场
福安药业:截止11月20日股东户数为39313户
证券之星 · 11-24
福安药业:截止11月20日股东户数为39313户
11月14日福安药业现1笔折价10.76%的大宗交易 合计成交423万元
证券之星 · 11-14
11月14日福安药业现1笔折价10.76%的大宗交易 合计成交423万元
福安药业(300194.SZ)子公司收到菲律宾GMP符合性证书
智通财经网 · 11-05
福安药业(300194.SZ)子公司收到菲律宾GMP符合性证书
福安药业:截止10月31日股东户数为39204户
证券之星 · 11-05
福安药业:截止10月31日股东户数为39204户
福安药业(300194)2025年三季报简析:净利润同比下降44.87%
证券之星 · 10-29
福安药业(300194)2025年三季报简析:净利润同比下降44.87%
福安药业(300194.SZ)发布前三季度业绩,归母净利润1.66亿元,下降44.87%
智通财经 · 10-27
福安药业(300194.SZ)发布前三季度业绩,归母净利润1.66亿元,下降44.87%
福安药业:截止10月20日股东户数为38924户
证券之星 · 10-27
福安药业:截止10月20日股东户数为38924户
福安药业:麻醉药品获批时间较短将拓展市场
证券之星 · 10-15
福安药业:麻醉药品获批时间较短将拓展市场
福安药业:截止9月30日股东户数为39007户
证券之星 · 10-10
福安药业:截止9月30日股东户数为39007户
股市必读:福安药业(300194)9月26日披露最新机构调研信息
证券之星 · 09-29
股市必读:福安药业(300194)9月26日披露最新机构调研信息
福安药业(300194)9月20日股东户数3.92万户,较上期减少4.13%
证券之星 · 09-25
福安药业(300194)9月20日股东户数3.92万户,较上期减少4.13%
股市必读:福安药业(300194)9月22日董秘有最新回复
证券之星 · 09-23
股市必读:福安药业(300194)9月22日董秘有最新回复
福安药业:积极适应行业政策变化应对风险挑战
证券之星 · 09-22
福安药业:积极适应行业政策变化应对风险挑战
福安药业(300194)披露2025年半年度权益分派实施公告,9月17日股价下跌0.43%
证券之星 · 09-17
福安药业(300194)披露2025年半年度权益分派实施公告,9月17日股价下跌0.43%
福安药业(300194)8月29日股东户数4.09万户,较上期增加1.67%
证券之星 · 09-08
福安药业(300194)8月29日股东户数4.09万户,较上期增加1.67%
加载更多
公司概况
公司名称:
福安药业(集团)股份有限公司
所属行业:
医药制造业
上市日期:
2011-03-22
主营业务:
福安药业(集团)股份有限公司的主营业务是化学药品的研发、生产、销售。公司的主要产品是庆大霉素、头孢唑肟钠、头孢美唑钠、拉氧头孢钠、头孢他啶、枸橼酸托瑞米芬片(制剂)、盐酸昂丹司琼(原料药、制剂)、盐酸格拉司琼(原料药、制剂)、多索茶碱(原料药、制剂)、尼麦角林胶囊、舒林酸片、谷胱甘肽。
发行价格:
41.88
{"stockData":{"symbol":"300194","market":"SZ","secType":"STK","nameCN":"福安药业","latestPrice":4.48,"timestamp":1765436637000,"preClose":4.56,"halted":0,"volume":20042325,"delay":0,"changeRate":-0.0175,"floatShares":968000000,"shares":1190000000,"eps":0.1215,"marketStatus":"已收盘","change":-0.08,"latestTime":"12-11 15:00:00","open":4.56,"high":4.6,"low":4.47,"amount":90817100,"amplitude":0.0285,"askPrice":4.48,"askSize":1047,"bidPrice":4.47,"bidSize":1795,"shortable":0,"etf":0,"ttmEps":0.1215,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1765503000000},"marketStatusCode":5,"adr":0,"adjPreClose":4.56,"symbolType":"stock","openAndCloseTimeList":[[1765416600000,1765423800000],[1765429200000,1765436400000]],"highLimit":5.02,"lowLimit":4.1,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":1189712382,"isCdr":false,"pbRate":1.22,"roa":"--","peRate":36.872428,"roe":"3.73%","epsLYR":0.24,"committee":0.101789,"marketValue":5330000000,"turnoverRate":0.0207,"status":1,"floatMarketCap":4338000000},"requestUrl":"/m/hq/s/300194","defaultTab":"news","newsList":[{"id":"2590382715","title":"福安药业(300194)披露子公司收到药品注册证书,12月10日股价上涨1.56%","url":"https://stock-news.laohu8.com/highlight/detail?id=2590382715","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590382715?lang=zh_cn&edition=full","pubTime":"2025-12-10 22:15","pubTimestamp":1765376150,"startTime":"0","endTime":"0","summary":"截至2025年12月10日收盘,福安药业报收于4.56元,较前一交易日上涨1.56%,最新总市值为54.25亿元。该股当日开盘4.48元,最高4.59元,最低4.44元,成交额达9351.98万元,换手率为2.13%。公司于近日发布公告称,其全资子公司福安药业集团湖北人民制药有限公司近日收到国家药品监督管理局签发的注射用硫酸艾沙康唑药品注册证书,批准文号为国药准字H20256127,注册分类为化学药品4类,规格0.2g,适用于治疗成人侵袭性曲霉病和侵袭性毛霉病。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121000041588.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0060","300194","BK0132","BK0239","BK0028"],"gpt_icon":0},{"id":"2589622338","title":"福安药业(300194.SZ)子公司产品纳入国家医保药品目录","url":"https://stock-news.laohu8.com/highlight/detail?id=2589622338","media":"智通财经","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589622338?lang=zh_cn&edition=full","pubTime":"2025-12-08 16:11","pubTimestamp":1765181474,"startTime":"0","endTime":"0","summary":"智通财经APP讯,福安药业(300194.SZ)公告,据国家医保局、人力资源社会保障部发布《关于印发<国家基本医疗保险、生育保险和工伤保险药品目录>(2025年)的通知》,公司下属子公司产品帕拉米韦注射液被纳入《国家医保药品目录》。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1378755.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"福安药业(300194.SZ)子公司产品纳入国家医保药品目录","news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0060","300194","BK0132","BK0028","BK0239"],"gpt_icon":0},{"id":"2588576080","title":"福安药业:多维度提升管理效能","url":"https://stock-news.laohu8.com/highlight/detail?id=2588576080","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588576080?lang=zh_cn&edition=full","pubTime":"2025-12-02 15:31","pubTimestamp":1764660662,"startTime":"0","endTime":"0","summary":"证券之星消息,福安药业12月02日在投资者关系平台上答复投资者关心的问题。未来,公司将持续提高研发水平、努力开拓市场,多维度提升管理效能,积极推动公司的可持续发展和盈利能力提升。在努力为股东创造长期价值回报的基础上,公司将通过多渠道与投资者保持良好互动交流,积极向市场传递公司投资价值。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120200017196.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0060","BK0239","BK0028","BK0132","300194"],"gpt_icon":0},{"id":"2588571747","title":"福安药业(300194.SZ):“头孢托仑匹酯颗粒”获得药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2588571747","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588571747?lang=zh_cn&edition=full","pubTime":"2025-12-01 16:11","pubTimestamp":1764576672,"startTime":"0","endTime":"0","summary":"智通财经APP讯,福安药业 发布公告,公司全资子公司福安药业集团庆余堂制药有限公司于近日收到国家药品监督管理局签发的药品注册证书,涉及药品:“头孢托仑匹酯颗粒”。根据国家药品监督管理局数据查询信息平台显示,截止目前,该药品共有2家企业通过一致性评价或视同通过一致性评价。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1375936.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"福安药业(300194.SZ):“头孢托仑匹酯颗粒”获得药品注册证书","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0060","300194","BK0239","BK0028","BK0132"],"gpt_icon":0},{"id":"2586820204","title":"福安药业:子公司积极拓展海外市场","url":"https://stock-news.laohu8.com/highlight/detail?id=2586820204","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586820204?lang=zh_cn&edition=full","pubTime":"2025-11-28 16:42","pubTimestamp":1764319329,"startTime":"0","endTime":"0","summary":"证券之星消息,福安药业(300194)11月28日在投资者关系平台上答复投资者关心的问题。投资者提问:公司产品除了拿到菲律宾的许可外,在其他的国家公司有没有进一步拓展业务的规划福安药业回复:公司子公司近年来积极拓展海外市场,部分产品线除通过菲律宾GMP检查外,也有场地通过美国FDA检查,产品获得韩国药品注册证书等等,您可在指定信息披露媒体查阅相关公告,未来,公司仍将积极寻求拓展海外业务机会,进一步提升公司抗风险能力,谢谢!以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112800022131.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300194","BK0028","BK0239","BK0060","BK0132"],"gpt_icon":0},{"id":"2585459347","title":"福安药业:截止11月20日股东户数为39313户","url":"https://stock-news.laohu8.com/highlight/detail?id=2585459347","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585459347?lang=zh_cn&edition=full","pubTime":"2025-11-24 15:18","pubTimestamp":1763968703,"startTime":"0","endTime":"0","summary":"证券之星消息,福安药业(300194)11月24日在投资者关系平台上答复投资者关心的问题。投资者提问:尊敬的董秘,请问截止到11月20日的最新股东人数是多少,谢谢!福安药业回复:截止11月20日,公司股东户数为39313户,谢谢!以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112400012736.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0060","BK0239","BK0028","300194","BK0132"],"gpt_icon":0},{"id":"2583230579","title":"11月14日福安药业现1笔折价10.76%的大宗交易 合计成交423万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2583230579","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583230579?lang=zh_cn&edition=full","pubTime":"2025-11-14 17:25","pubTimestamp":1763112308,"startTime":"0","endTime":"0","summary":"证券之星消息,11月14日福安药业发生大宗交易,交易数据如下:大宗交易成交价格4.23元,相对当日收盘价折价10.76%,成交100万股,成交金额423万元,买方营业部为中国中金财富证券有限公司海南分公司,卖方营业部为中国中金财富证券有限公司海南分公司。近三个月该股共发生1笔大宗交易,合计成交1.0万手,折价成交1笔。该股近期无解禁股上市。截至2025年11月14日收盘,福安药业报收于4.74元,上涨0.21%,换手率2.5%,成交量24.22万手,成交额1.15亿元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111400027717.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0060","300194","BK0132","BK0028","BK0239"],"gpt_icon":0},{"id":"2581174694","title":"福安药业(300194.SZ)子公司收到菲律宾GMP符合性证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2581174694","media":"智通财经网","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2581174694?lang=zh_cn&edition=full","pubTime":"2025-11-05 16:05","pubTimestamp":1762329946,"startTime":"0","endTime":"0","summary":"智通财经APP讯,福安药业(300194.SZ)发布公告,公司全资子公司福安药业集团庆余堂制药有限公司(简称“庆余堂”)于近日收到菲律宾共和国卫生部食品药品监督管理局签发的《GMP符合性证书》。更多港股重磅资讯,下载智通财经app更多港股及海外理财资讯,请点击www.zhitongcaijing.com(搜索“智通财经”);欲加入智通港股投资群,请加智通客服微信(ztcjkf)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1365499.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK0132","300194","BK0028","BK0060","BK0239"],"gpt_icon":0},{"id":"2581279490","title":"福安药业:截止10月31日股东户数为39204户","url":"https://stock-news.laohu8.com/highlight/detail?id=2581279490","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2581279490?lang=zh_cn&edition=full","pubTime":"2025-11-05 08:45","pubTimestamp":1762303519,"startTime":"0","endTime":"0","summary":"证券之星消息,福安药业(300194)11月04日在投资者关系平台上答复投资者关心的问题。投资者提问:请问贵公司截止到十月底股东人数是多少?福安药业回复:截止10月31日,公司股东户数为39204户,谢谢!以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110500005650.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0060","300194","BK0028","BK0132","BK0239"],"gpt_icon":0},{"id":"2579916563","title":"福安药业(300194)2025年三季报简析:净利润同比下降44.87%","url":"https://stock-news.laohu8.com/highlight/detail?id=2579916563","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579916563?lang=zh_cn&edition=full","pubTime":"2025-10-29 06:38","pubTimestamp":1761691082,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理,近期福安药业发布2025年三季报。根据财报显示,福安药业净利润同比下降44.87%。截至本报告期末,公司营业总收入13.15亿元,同比下降34.08%,归母净利润1.66亿元,同比下降44.87%。按单季度数据看,第三季度营业总收入3.95亿元,同比下降29.77%,第三季度归母净利润5314.2万元,同比下降37.57%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102900010491.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300194"],"gpt_icon":0},{"id":"2578615557","title":"福安药业(300194.SZ)发布前三季度业绩,归母净利润1.66亿元,下降44.87%","url":"https://stock-news.laohu8.com/highlight/detail?id=2578615557","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2578615557?lang=zh_cn&edition=full","pubTime":"2025-10-27 16:52","pubTimestamp":1761555155,"startTime":"0","endTime":"0","summary":"智通财经APP讯,福安药业(300194.SZ)发布2025年三季度报告,该公司前三季度营业收入为13.15亿元,同比减少34.08%。归属于上市公司股东的净利润为1.66亿元,同比减少44.87%。归属于上市公司股东的扣除非经常性损益的净利润为1.48亿元,同比减少47.53%。基本每股收益为0.14元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1360388.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":"福安药业(300194.SZ)发布前三季度业绩,归母净利润1.66亿元,下降44.87%","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["300194"],"gpt_icon":0},{"id":"2578013690","title":"福安药业:截止10月20日股东户数为38924户","url":"https://stock-news.laohu8.com/highlight/detail?id=2578013690","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2578013690?lang=zh_cn&edition=full","pubTime":"2025-10-27 15:51","pubTimestamp":1761551467,"startTime":"0","endTime":"0","summary":"证券之星消息,福安药业(300194)10月27日在投资者关系平台上答复投资者关心的问题。投资者提问:董秘您好!请问截止10月20号,公司的股东人数是多少?谢谢福安药业回复:截止10月20日,公司股东户数为38924户,谢谢!以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102700018160.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300194","BK0028","BK0060","BK0132"],"gpt_icon":0},{"id":"2575206769","title":"福安药业:麻醉药品获批时间较短将拓展市场","url":"https://stock-news.laohu8.com/highlight/detail?id=2575206769","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2575206769?lang=zh_cn&edition=full","pubTime":"2025-10-15 15:52","pubTimestamp":1760514736,"startTime":"0","endTime":"0","summary":"证券之星消息,福安药业(300194)10月15日在投资者关系平台上答复投资者关心的问题。投资者提问:公司麻醉药品销售量小的原因是产品质量问题还是价格问题?福安药业回复:麻醉药品是受国家严格管制的药品,实行定点生产制度,国家对麻醉药品实行全链条管控,以防止滥用和非法流通。公司相关药品获得批件时间较短,将在在遵守国家法规的前提下拓展相关市场,谢谢!以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025101500022426.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0132","BK0028","BK0060","300194"],"gpt_icon":0},{"id":"2574476381","title":"福安药业:截止9月30日股东户数为39007户","url":"https://stock-news.laohu8.com/highlight/detail?id=2574476381","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2574476381?lang=zh_cn&edition=full","pubTime":"2025-10-10 15:08","pubTimestamp":1760080101,"startTime":"0","endTime":"0","summary":"证券之星消息,福安药业(300194)10月10日在投资者关系平台上答复投资者关心的问题。投资者提问:请问截止2025年9月30日公司股东人数有多少?谢谢福安药业回复:截止9月30日,公司股东户数为39007户,谢谢!以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025101000017875.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0132","BK0060","300194","BK0028"],"gpt_icon":0},{"id":"2571217408","title":"股市必读:福安药业(300194)9月26日披露最新机构调研信息","url":"https://stock-news.laohu8.com/highlight/detail?id=2571217408","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2571217408?lang=zh_cn&edition=full","pubTime":"2025-09-29 03:43","pubTimestamp":1759088590,"startTime":"0","endTime":"0","summary":"截至2025年9月26日收盘,福安药业报收于4.29元,上涨0.0%,换手率1.09%,成交量10.58万手,成交额4547.2万元。来自机构调研要点:公司回应美国子公司回购纠纷称诉讼仍在进行中,将通过法律途径维护权益。截至9月20日,公司股东户数为39,180户。公司在美国的投资款项回收情况需待诉讼结果,进展将依规披露。公司未收到关于富民银行上市计划的相关信息。三季度经营业绩将按期披露,敬请关注后续公告。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025092900001368.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0028","BK0132","300194","BK0060"],"gpt_icon":0},{"id":"2570209866","title":"福安药业(300194)9月20日股东户数3.92万户,较上期减少4.13%","url":"https://stock-news.laohu8.com/highlight/detail?id=2570209866","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2570209866?lang=zh_cn&edition=full","pubTime":"2025-09-25 17:33","pubTimestamp":1758792789,"startTime":"0","endTime":"0","summary":"证券之星消息,近日福安药业披露,截至2025年9月20日公司股东户数为3.92万户,较8月29日减少1687.0户,减幅为4.13%。在化学制药行业个股中,福安药业股东户数高于行业平均水平,截至9月20日,化学制药行业平均股东户数为3.24万户。从股价来看,2025年8月29日至2025年9月20日,福安药业区间跌幅为3.7%,在此期间股东户数减少1687.0户,减幅为4.13%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025092500025660.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0239","300194","BK0132","BK0060"],"gpt_icon":0},{"id":"2569404732","title":"股市必读:福安药业(300194)9月22日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2569404732","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2569404732?lang=zh_cn&edition=full","pubTime":"2025-09-23 02:47","pubTimestamp":1758566832,"startTime":"0","endTime":"0","summary":"董秘最新回复投资者: 面对行业政策变化和市场环境的不确定性,公司长期发展战略是什么?董秘: 公司目前仍以国内市场为主,近些年一直有开拓国际市场,但总体外贸收入占比较小,2024年出口收入约占营收的比重为2.8%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025092300001782.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0060","BK0132","300194","BK0239"],"gpt_icon":0},{"id":"2569456209","title":"福安药业:积极适应行业政策变化应对风险挑战","url":"https://stock-news.laohu8.com/highlight/detail?id=2569456209","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2569456209?lang=zh_cn&edition=full","pubTime":"2025-09-22 15:12","pubTimestamp":1758525126,"startTime":"0","endTime":"0","summary":"证券之星消息,福安药业(300194)09月22日在投资者关系平台上答复投资者关心的问题。投资者提问:面对行业政策变化和市场环境的不确定性,公司长期发展战略是什么?如何确保可持续发展?福安药业回复:行业政策变化和市场环境变化的不确定性对所有业内企业都是一样存在的,公司将积极适应行业政策变化,妥善应对风险挑战,寻找未来发展机遇,努力做好生产经营各项工作,谢谢!以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025092200014101.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0060","BK0132","BK0028","300194"],"gpt_icon":0},{"id":"2568505497","title":"福安药业(300194)披露2025年半年度权益分派实施公告,9月17日股价下跌0.43%","url":"https://stock-news.laohu8.com/highlight/detail?id=2568505497","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2568505497?lang=zh_cn&edition=full","pubTime":"2025-09-17 22:48","pubTimestamp":1758120496,"startTime":"0","endTime":"0","summary":"截至2025年9月17日收盘,福安药业报收于4.62元,较前一交易日下跌0.43%,最新总市值为54.96亿元。该股当日开盘4.64元,最高4.65元,最低4.59元,成交额达7690.07万元,换手率为1.72%。公司近日发布公告称,2025年半年度权益分派方案已获2025年9月15日召开的2025年第一次临时股东大会审议通过。本次权益分派对象为截至2025年9月24日下午深圳证券交易所收市后在中国证券登记结算有限责任公司深圳分公司登记在册的全体股东。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025091700040671.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0060","300194","BK0239","BK0132","BK0028"],"gpt_icon":0},{"id":"2565502142","title":"福安药业(300194)8月29日股东户数4.09万户,较上期增加1.67%","url":"https://stock-news.laohu8.com/highlight/detail?id=2565502142","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2565502142?lang=zh_cn&edition=full","pubTime":"2025-09-08 17:21","pubTimestamp":1757323267,"startTime":"0","endTime":"0","summary":"证券之星消息,近日福安药业披露,截至2025年8月29日公司股东户数为4.09万户,较8月8日增加672.0户,增幅为1.67%。在化学制药行业个股中,福安药业股东户数高于行业平均水平,截至8月29日,化学制药行业平均股东户数为3.27万户。从股价来看,2025年8月8日至2025年8月29日,福安药业区间涨幅为0.44%,在此期间股东户数增加672.0户,增幅为1.67%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025090800022748.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0060","BK0132","BK0239","300194","BK0028"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1765458500634,"stockEarnings":[{"period":"1week","weight":-0.013},{"period":"1month","weight":-0.0194},{"period":"3month","weight":0.0046},{"period":"6month","weight":0.0704},{"period":"1year","weight":-0.0854},{"period":"ytd","weight":0.0397}],"compareEarnings":[{"period":"1week","weight":0.0058},{"period":"1month","weight":-0.0294},{"period":"3month","weight":0.0065},{"period":"6month","weight":0.155},{"period":"1year","weight":0.1396},{"period":"ytd","weight":0.1637}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"福安药业(集团)股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"39120人(较上一季度减少0.49%)","perCapita":"24753股","listingDate":"2011-03-22","address":"重庆市长寿区化南一路1号","registeredCapital":"118971万元","survey":" 福安药业(集团)股份有限公司的主营业务是化学药品的研发、生产、销售。公司的主要产品是庆大霉素、头孢唑肟钠、头孢美唑钠、拉氧头孢钠、头孢他啶、枸橼酸托瑞米芬片(制剂)、盐酸昂丹司琼(原料药、制剂)、盐酸格拉司琼(原料药、制剂)、多索茶碱(原料药、制剂)、尼麦角林胶囊、舒林酸片、谷胱甘肽。","listedPrice":41.88},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"福安药业(300194)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供福安药业(300194)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"福安药业,300194,福安药业股票,福安药业股票老虎,福安药业股票老虎国际,福安药业行情,福安药业股票行情,福安药业股价,福安药业股市,福安药业股票价格,福安药业股票交易,福安药业股票购买,福安药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"福安药业(300194)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供福安药业(300194)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}